PLX
Protalix BioTherapeutics, Inc.
$2.38
+0.02 (+0.85%)
At close · Jul 8
Market Cap
$191.76M
Shares
80,571,642
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$52.74M
-1.2%
FY2025
Net Income
-$6.6M
-325.2%
FY2025
Gross Margin
19.03%
+10.3pp
FY2017
Operating Margin
-10.43%
-17.8pp
FY2025
Diluted EPS
-$0.08
-300%
FY2025
Operating Cash Flow
-$11.99M
-238.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $76.38M | $52.74M | $53.4M | $65.49M | $47.64M | $38.35M | $62.9M | $54.69M | $34.24M | $21.08M | $9.2M | $4.36M | $3.52M | $0 | $34.87M | $8.39M | $6.64M | $388K | |
| $22.94M | $26.99M | $24.32M | $22.98M | $19.59M | $16.35M | $10.87M | $10.9M | $9.3M | $15.23M | $8.4M | $730K | $630K | $0 | $8.14M | $1.53M | $4.38M | $3.58M | |
| $1.11M | — | — | — | — | — | — | — | — | $4.01M | $801K | $3.63M | $2.89M | $0 | $26.28M | $1.44M | $6.86M | -$3.19M | |
| — | — | — | — | — | — | — | — | — | 19.03% | 8.71% | 83.27% | 82.12% | — | 75.37% | 17.21% | 103.3% | -821.39% | |
| $21.52M | $19.57M | $12.97M | $17.09M | $29.35M | $29.73M | $38.17M | $44.62M | $33.33M | $32.17M | $30.41M | $24.89M | $27.35M | $29.23M | $36.67M | $37.82M | $37.69M | $27.39M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $8.39M | $9.76M | $6.93M | $6.88M | $7.14M | |
| $12.13M | $11.68M | $12.19M | $14.96M | $11.71M | $12.73M | $11.15M | $9.9M | $10.92M | $11.53M | $9.36M | $7.28M | $9.23M | $8.05M | $9.76M | — | — | — | |
| $19.79M | -$5.5M | $3.92M | $10.46M | -$13.01M | -$20.46M | $2.71M | -$10.72M | -$19.31M | -$34.52M | -$33.16M | -$23.67M | -$28.56M | -$34.06M | -$12.17M | -$36.53M | -$29.97M | -$31.97M | |
| — | -10.43% | 7.34% | 15.97% | -27.32% | -53.36% | 4.31% | -19.59% | -56.39% | -163.76% | -360.51% | -542.39% | -810.64% | — | -34.91% | -435.62% | -451.16% | -8239.43% | |
| — | — | — | — | — | — | — | — | — | — | — | $3.55M | $3.55M | $1.02M | — | — | — | — | |
| -$526K | -$108K | $237K | -$1.89M | -$1.38M | -$7.12M | -$9.23M | -$7.56M | -$7.15M | -$48.92M | $3.99M | -$3.61M | -$4.74M | -$674K | $554K | $2000 | — | — | |
| $19.27M | -$5.61M | $4.15M | $8.57M | -$14.4M | -$27.58M | -$6.52M | — | — | — | — | — | — | — | — | — | — | — | |
| $3.93M | $996K | $1.22M | $254K | $530K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $15.33M | -$6.6M | $2.93M | $8.31M | -$14.93M | -$27.58M | -$6.52M | -$18.28M | -$26.46M | -$83.44M | -$29.37M | $58.04M | -$29.94M | -$27.79M | -$11.62M | -$36.53M | -$29M | -$31.44M | |
| — | -12.52% | 5.49% | 12.69% | -31.33% | -71.92% | -10.37% | -33.42% | -77.27% | -395.86% | -319.22% | 1329.9% | -849.93% | — | -33.32% | -435.6% | -436.59% | -8103.09% | |
| USD/shares | — | -$0.08 | $0.04 | $0.12 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.08 | $0.04 | $0.09 | -$0.31 | -$0.62 | -$0.22 | -$1.23 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 78.55M | 72.53M | 67.51M | 48.47M | 44.14M | 29.15M | 14.84M | 14.71M | 13.11M | 101.39M | 94.92M | 92.89M | 92.37M | 90.85M | 84.65M | 80.96M | — |
| shares | — | 78.55M | 81.06M | 82.42M | 48.47M | 44.14M | 29.15M | 14.84M | 14.71M | 13.11M | 101.39M | 94.92M | 92.89M | 92.37M | 90.85M | 84.65M | 80.96M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
12.53×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Single Operating Segment | $52,744,000 | $53,399,000 | $65,494,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $51,802,000 | $52,981,000 | $40,418,000 | $25,292,000 | $16,749,000 | $16,236,000 | $15,866,000 | $8,978,000 |
| License And Service | $942,000 | $418,000 | $25,076,000 | $22,346,000 | $21,601,000 | $46,662,000 | $38,827,000 | $25,262,000 |